TCBP Announces Transition from Nasdaq to OTC Markets
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2025
0mins
Source: Newsfilter
Delisting from Nasdaq: TC BioPharm has been notified of its delisting from the Nasdaq Stock Market due to non-compliance with minimum bid price requirements, effective March 24, 2025. The company is appealing this decision and will transition to trading on OTC Markets.
Commitment to Research: Despite the delisting, TC BioPharm remains dedicated to advancing its gamma-delta T cell therapies for cancer treatment and continues to conduct clinical trials, including pivotal studies for acute myeloid leukemia.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
